Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders

 
 

Inhibikase Therapeutics, Inc. Add to portfolio


Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18
Revenues0.13.10.71.14.0
            Revenue growth-96.0%343.9%-37.8%-72.2% 
Cost of goods sold0.00.03.52.63.6
Gross profit0.13.1-2.8-1.40.4
            Gross margin100.0%100.0%-403.5%-127.4%9.7%
Selling, general and administrative6.26.50.04.32.5
Research and development12.011.4   
EBIT-18.1-14.8-1.4-5.7-2.1
            EBIT margin-14686.2%-476.2%-201.1%-507.5%-52.5%
Pre-tax income-18.1-14.8-2.8-5.7-2.2
Income taxes0.00.00.00.00.0
            Tax rate0.0%0.0%0.0%0.0%0.0%
Net income-18.1-14.8-2.8-5.7-2.2
            Net margin-14625.9%-476.9%-407.7%-509.7%-53.3%
 
Diluted EPS($0.72)($0.81)($0.35)  
Shares outstanding (diluted)25.218.28.2  
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy